Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery

Howard M Fillit,Penny A Dacks,Rachel F Lane,Diana W Shineman

doi:10.1186/alzrt159

Abstract

The Alzheimer's Drug Discovery Foundation's 13th International Conference on Alzheimer's Drug Discovery was held on 10-11 September 2012 in Jersey City, NJ, USA. This meeting report provides an overview of Alzheimer's Drug Discovery Foundation-funded programs, ranging from novel biomarkers to accelerate clinical development to drug-discovery programs with a focus on targets related to neuroprotection, mitochondrial function, apolipoprotein E and vascular biology.

Highlights

The Alzheimer’s Drug Discovery Foundation’s 13th International Conference on Alzheimer’s Drug Discovery was held on 10–11 September 2012 in Jersey City, NJ, USA. This meeting report provides an overview of Alzheimer’s Drug Discovery Foundation-funded programs, ranging from novel biomarkers to accelerate clinical development to drug-discovery programs with a focus on targets related to neuroprotection, mitochondrial function, apolipoprotein E and vascular biology
A multitude of factors lead to the onset of neurodegenerative diseases, including mitochondrial dysfunction, altered lipid metabolism and dysregulation of intracellular trafficking and signaling pathways
Apolipoprotein E While the APOE4 allele was identified as a significant risk allele for late-onset Alzheimer’s disease (AD) in the early 1990s, to date there are no late-stage development programs targeting this pathological mechanism

Summary

Introduction

A multitude of factors lead to the onset of neurodegenerative diseases, including mitochondrial dysfunction, altered lipid metabolism and dysregulation of intracellular trafficking and signaling pathways. Diverse therapeutic targets and biomarkers for Alzheimer’s disease and related dementias: report on the Alzheimer’s Drug Discovery Foundation 2012 International Conference on Alzheimer’s Drug Discovery This meeting report provides an overview of Alzheimer’s Drug Discovery Foundation-funded programs, ranging from novel biomarkers to accelerate clinical development to drug-discovery programs with a focus on targets related to neuroprotection, mitochondrial function, apolipoprotein E and vascular biology.

Results

Conclusion